Taking these results into consideration, we assume that APT-F2P might be effective in ameliorating chronic pain associated with FGF2 overproduction, such as in bone cancer, but not acute pain unassociated with FGF2 overproduction, such as in immediate postoperation. The gene discussed is FGF2; the disease is bone cancer.